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Abstract A site-directed anti-peptide antibody (anti- 
hGHRHRcl8) was generated against the cytoplasmic tail of 
human GHRH receptor. The dissociation constant (Kd) and the 
antibody binding site (AbT) of anti-hGHRHRcl8 were 2.5 nmol/ 
I and 0.54 nmol/l, respectively. In an immunoblotting experiment, 
affinity-purified anti-hGHRHR¢18 specifically recognized a 
single 50-kDa protein in human pituitary. In a screening of the 
expression of GHRH receptor protein in extra-pituitary tissues, 
only human kidney showed a single 52-kDa protein. Our results 
suggest hat the GHRH receptor protein exhibits tissue-specific 
molecular heterogeneity. 
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cloned from the pituitary. Furthermore, the tissue distribution 
of GHRH receptor was studied by measuring GHRH recep- 
tor mRNA,  and an absence of GHRH receptor mRNA ex- 
pression was found in extra-pituitary tissues [21 23]. How- 
ever, these studies cannot exclude the possibility of technical 
problems, since the usual method for detecting mRNA expres- 
sion is not sensitive enough to detect a minor population of 
mRNA.  
In this study, we generated a site-specific anti-peptide anti- 
body against the cytoplasmic tail of GHRH receptor protein 
and examined the presence of GHRH receptor protein in ex- 
tra-pituitary tissues. 
2. Materials and methods 
1. Introduction 
Growth hormone-releasing hormone (GHRH)  is a hypotha- 
lamic releasing hormone which stimulates GH secretion from 
pituitary somatotrophs [1,2]. This activity was first isolated 
and characterized in human pancreatic islet tumors accompa- 
nying acromegaly [3,4] and was subsequently found to be 
identical to hypothalamic GHRH [5,6]. GHRH is produced 
mainly in the arcuate nucleus and is released into the hypo- 
physial portal vein at the median eminence [7]. The released 
GHRH acts directly on pituitary somatotrophs through a G- 
protein-coupled receptor to stimulate adenylyl cyclase, result- 
ing in the synthesis and release of growth hormone (GH) in 
the anterior pituitary. Since the discovery of GHRH,  the pres- 
ence of extra-hypothalamic GHRH has been reported in leu- 
kocytes, testis, ovary, placenta, endometrium, pancreas, and 
gastrointestinal tract [2,8-17]. However, it has not yet been 
determined whether these extra-hypothalamic GHRHs have 
any physiological significance. Additional evidence has sug- 
gested that these extra-hypothalamic GHRHs might use the 
VIP receptor, since the VIP receptor can bind GHRH [18 20]. 
To clarify the physiological significance of  extra-hypothalamic 
GHRH,  it is critical to determine whether these GHRH-posi -  
tive extra-hypothalamic tissues coexpress GHRH receptor. 
Since GHRH binds with the VIP receptor and other secre- 
tin-family receptors, we cannot use a binding assay or chemi- 
cal cross-linking analysis to address these questions. 
A cDNA encoding GHRH receptor has recently been 
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2.1. Preparation of anti-hGHRHRcl8 
A synthetic oligopeptide (hGHRHRcl8: TRAKWTTPSR- 
SAAKVLTS) corresponding to the amino acid residue 404421 of 
human GHRH receptor [21] was chemically synthesized by a solid- 
phase method. This hGHRHRcl8 has 67% homology with the corre- 
sponding rat GHRH receptor protein (TCTEWTTPPRSRVKVLTS). 
5 mg of hGHRHRcl8 was conjugated with 20 mg of keyhole limpet 
hemocyanin (KLH) using glutaraldehyde. The conjugate was emulsi- 
fied with complete Freund's adjuvant and injected subcutaneously 
into multiple sites over the backs of three male Japanese White rabbits 
(600 lag peptide/rabbit). All of the rabbits received booster injections 
of the conjugate mulsified with incomplete Freund's adjuvant at 14, 
28, 42, 56, 70, 84, and 98 days after the initial immunization (450 ~tg/ 
rabbit/boost). 10 ml of whole blood was obtained from the ear vein of 
each rabbit at each time point. Serum was separated from each blood 
sample and stored at -80°C until use. 
2.2. RIA of hGHRHRcl8 
The specificity and titer of anti-hGHRHRcl8 was assessed by 
radioimmunoassay (RIA). Since hGHRHRcl8 does not contain a 
tyrosine residue, Tyr-hGHRHRel8 containing Tyr at the N-terminal 
of hGHRHRcl 8 was synthesized. Tyr-hGHRHRcl 8 (5 lag) was radio- 
iodinated with 1 mCi of 125I by the Iodogen method. A mixture of 0.2 
ml of assay buffer (0.1 mol/1 phosphate buffer, pH 7.4, containing 0.14 
moll1 of NaC1, 0.05 mol/l of EDTA, 0.01% NAN3, 0.1% BSA, and 
0.1% Triton X-100), 0.05 ml of diluted anti-hGHRHRcl 8 serum (final 
dilution, 1:4200) and 0.05 ml of standard Tyr-hGHRHRcl8 was in- 
cubated at 4°C for 24 h. lodinated Tyr-hGHRHRcl8 0.05 ml (about 
5000 cpm) was then added, and the incubation was continued at 4°C 
for 24 h. Thereafter, 0.05 ml of anti-rabbit gamma-globulin (final 
dilution, 1:135) and 0.05 ml of normal rabbit serum (final dilution, 
1:1350) were added. After incubation at 4°C for an additional 24 h, 
the mixture was centrifuged at 4°C for 30 min at 2000xg and the 
radioactivity of the precipitate was counted in a gamma counter (Alo- 
ka, Tokyo), All determinations were performed in duplicate. The dis- 
sociation constant (Kd) and concentration of the antibody binding site 
(AbT) values were calculated by Scatchard analysis. 
2.3. Immunoaffinity purification of anti-hGHRHRcl8 
An hGHRHRc18-immobilized immunoaffinity column was pre- 
pared using 1 ml of Affi-Gel 10 (Bio-Rad Laboratories, Richmond, 
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Fig. 1. Dissociation curves in radioimmunoassays for the synthetic Tyr-GHRH receptor fragment peptide. The specific binding of antiserum 
against he synthetic peptide was estimated by self-displacement (A). A Scatchard plot (B) revealed that the dissociation constant (Kd) and the 
antibody binding site concentration (AbT) were 2.5 and 0.54 nmol/l, respectively. 
CA) and 1 mg of hGHRHRcI8 following the protocol provided by 
the manufacturer. The IgG fraction of anti-hGHRHRcl8 was pre- 
pared using protein A chromatography (Ampure PA kit: Amersham, 
Buckinghamshire, UK). The IgG fractions of anti-hGHRHRcl8 were 
added to the hGHRHRcl8-immobilized column and shaken for 12 h 
at 4°C. The column was washed with TBS (0.02 mol/l Tris-HC1, pH 
7.5, 0.15 mol/l NaCI), followed by washing buffer (0.02 mol/l Tris- 
HCI, pH 7.5, 1 mol/1 NaCI, 1% Triton X-100), TBS and 0.15 mol/l 
NaC1. Anti-hGHRHRcl8 IgG fractions were eluted with elution buf- 
fer (0.1 mol/l glycine-HC1, pH 2.3). After neutralization with 1 mol/l 
Tris-HCl, pH 7.5, the protein concentrations in the fractions were 
measured with a BCA reagent kit (Amersham) and stored at -80°C. 
2.4. Preparation of the membrane fraction 
Human placenta was obtained from a woman at normal delivery 
and postmortem specimens of human pituitary, lung, liver, adrenal 
gland, kidney and ovary were obtained from two patients who had no 
endocrine disorders. Normal rat pituitary was also used in the study. 
Tissues were homogenized in ice-cold homogenate buffer (0.9% NaC1, 
0.001 mol/l EDTA, 0.01 mol/l Tris-HC1, pH 7.4) in the presence of 
protease inhibitors (0.1 mg/l of leupeptin, 0.1 mg/1 of chymostatin, 0.1 
mg/l of pepstatin and 0.5 U/1 of aprotinin) using a loose-fitting lass 
homogenizer. The homogenates were centrifuged at 750 x g for 30 min 
at 4°C and the supernatants were centrifuged at 27 000 X g for 20 min, 
The pellets were washed three times with each homogenate buffer 
containing various concentrations of NaC1 (0.5 mol/l, 1.0 moll1 and 
2.0 moll1). After resuspension with homogenate buffer containing 10% 
(v/v) glycerol and protease inhibitors, the membrane fractions were 
stored at -80°C until use. 
2.5. Immunoblotting 
Membrane fractions (100 lag protein) were resolved by 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) un- 
der reducing conditions and electrophoretically transferred onto nitro- 
cellulose membranes. The membrane was immersed in blocking buffer 
(5% nonfat dry milk in PBS) for 2 h at room temperature and in- 
cubated overnight at 4°C in a 1:600 dilution of purified anti- 
hGHRHRcl8 in blocking buffer. The immunoblot was washed three 
times with blocking buffer containing 0.05% Tween-20 (10 min each 
wash), and then incubated in a 1:2000 dilution of horseradish perox- 
idase-labeled goat anti-rabbit IgG (Zymed Laboratories Inc., San 
Francisco, CA) for 2 h at room temperature. After washing, the 
membrane was visualized with an enhanced chemiluminescence kit 
(Amersham) and exposed to Kodak AR X-ray film (Eastman Kodak, 
Rochester, NY). In addition, an absorption test using hGHRHRcl8 
(100 lag/ml diluted antiserum) was also performed. 
3. Results and discussion 
All three of the rabbits that had been immunized with the 
synthetic oligopeptide hGHRHRc l8  corresponding to the C- 
terminal intracellular tail of human GHRH receptor, pro- 
duced antisera with high titers, which reached a maximum 
at 105 days after the initial immunization. The calculated 
maximal Kd and AbT values were 2.5 nmol/l and 0.54 nmol/ 
1, respectively (Fig. 1). 
Immunoblotting using affinity-purified ant i -hGHRHRcl8  
showed a single specific band corresponding to a protein of 
about 50 kDa in human pituitary, and a 54-kDa protein in rat 
pituitary (Fig. 2). In spite of the fact that the molecular weight 
of human GHRH receptor protein predicted from the cDNA 
sequence was 45 kDa, previous studies using chemical cross- 
linking and GHRH analogs have provided conflicting results 
regarding the molecular weight of native GHRH receptor 
proteins: 75 kDa in human pituitary [24], 26 kDa in rat pi- 
tuitary [25], and 42 and 27 kDa in rat thymocytes and sple- 
nocytes [26], respectively. There has also been a report that 
the 75-kDa band in human pituitary was in fact nonspecific 
binding of GHRH to bovine serum albumin which was pres- 
ent in the reaction buffer [25]. These discrepancies clearly 
demonstrate the methodological imitations of chemical 
cross-linking studies, and the possible tissue-specific modifica- 
tion of GHRH receptor protein. Recently, a photoaffinity 
cross-linking study showed a 55-kDa band of GHRH receptor 
proteins, which shifted to 45 kDa after deglycosylation by N- 
glycosidase, in the membrane fraction of HEK-293 cells trans- 
fected with human GHRH receptor [27], suggesting that the 
differences in molecular weight observed in chemical cross- 
linking are due to differences in the tissue- or species-specific 
glycosylation of GHRH receptor proteins. Our results also 
clearly showed a difference in the molecular weight of 
GHRH receptor proteins between human and rat pituitaries. 
Immunoblotting of extra-pituitary tissues, including human 
lung, liver, adrenal gland, kidney, ovary, and placenta, 
showed no significant band except for human kidney (whole 
kidney was used for immunoblotting), which showed a single 
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Fig. 2. lmmunoblots of membrane fractions obtained from various 
tissues using anti-hGHRHRcl8. GHRH receptor immunoreactivities 
corresponding to 54-kDa, 50-kDa, and 52-kDa protein were identi- 
fied in the rat pituitary, human pituitary and human kidney, respec- 
tively. 
band corresponding to a 52-kDa protein (Fig. 2). There has 
been no report on GHRH immunoreactivity in the kidney, 
and Northern blot analysis has failed to show the expression 
of GHRH receptor mRNA in any extra-pituitary tissues, in- 
cluding the kidney [21--23]. Thus, our results are the first to 
demonstrate the presence of GHRH receptor protein in hu- 
man extra-pituitary tissues and the presence of a kidney-spe- 
cific molecular form of GHRH receptor, suggesting that it 
may regulate the activity of nephrotic ells, which is in stark 
contrast o the classical role of GHRH,  i.e. GH release from 
somatotrophs. 
There has been a report that GHRH or GH transgenic mice 
develop glomerulosclerosis, while IGF-1 transgenic mice do 
not [28]. Originally, these results were thought to indicate a 
direct action of GH on nephrotic ells. However, the possibil- 
ity of some direct action of GHRH on nephrotic ells should 
not be excluded. In addition, dwarf little (lit) mice with a 
missense mutation in the GHRH receptor gene showed no 
renal dysfunction [29,30]. Therefore, further analysis is re- 
quired to clarify the biological significance of the GHRH/  
GHRH receptor system in the kidney. 
The molecular heterogeneity of GHRH receptor proteins 
may result from tissue-specific alternative splicing or post- 
translational glycosylation of GHRH receptor protein, since 
several alternative forms of pituitary GHRH receptor cDNAs 
have been reported [21,31-33]. We should note the possibility 
of a truncated form of GHRH receptor which lacks the C- 
terminal cytoplasmic tail, which is necessary for recognition 
by ant i -hGHRHRcl  8. If extra-pituitary tissues expressed such 
truncated GHRH receptor proteins, our ant i -hGHRHRcl8 
would not be able to detect such subtypes of the GHRH 
receptor. Therefore, we cannot exclude the possibility that 
extra-pituitary tissues other than the kidney, which failed to 
show any band in our study, may express these truncated 
GHRH receptor proteins. Recently, Matsubara et al. reported 
the expression of GHRH and GHRH mRNA in various ex- 
tra-pituitary tissues, including the kidney, using RT-PCR [34]. 
Their primer set used for detection of GHRH receptor 
mRNA covered the N-terminal region, so it could detect all 
of the alternative GHRH receptor mRNA. Other anti-peptide 
antibodies that recognize subtype-specific sequences must be 
developed to clarify these problems. 
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